Close Menu

NEW YORK – Merck said after the close of the market on Monday that the US Food and Drug Administration has, at this time, decided not to approve pembrolizumab (Keytruda) as a neoadjuvant and adjuvant treatment for high-risk, early-stage triple-negative breast cancer (TNBC).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.